
    
      To estimate the efficacy of continuous use of alefacept (15mg IM/week) in the treatment of
      moderate to severe chronic plaque type psoriasis as defined as Investigator Global Assessment
      (IGA) of 0 or 1 (clear or almost clear) or as a 75% reduction in Psoriasis Area and Severity
      Index (PASI).
    
  